Study S002134

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07794579
Acronym: ATTAIN-NOW
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 2001
Start: 2026-08-26
Primary completion: 2029-08
Lead sponsor: Eli Lilly and Company
Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZVA; CTIS:2026-526175-35-00

Registered primary outcomes

Time to Onset of Obesity Related Complications or Class 1 Obesity [Baseline to Week 104]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.